DEC 19, 2017 3:10 PM PST

'Junk' Gene Implicated in Cancer's Growth

WRITTEN BY: Xuan Pham

Image credit: Pixabay.com

One of the biggest surprise findings from the completion of the Human Genome Project was that only 1.5 percent of our genome encodes for all of the protein-coding genes. The rest of our genome has been unfairly described as “junk” DNA.

But amidst this so-called genomic junk, scientists are finding sequences that modulate cellular processes and affect health and disease. Case in point, researchers from the University of Michigan recently discovered a ‘junk’ gene that has a “direct impact” on cancer development.

The research team began by combing the cell’s transcriptome – that is, the single-stranded RNA portion of the genetic code that’s been transcribed from DNA. Several types of RNAs make up the transcriptome. Among these is a particular molecule class known as long non-coding RNAs (lncRNAs). These transcripts are greater than 200 nucleotides but do not code for any proteins.

When the team dug further, they discovered a lncRNA that stood out from the rest. Called Testis-associated Highly-conserved Oncogenic long non-coding RNA, or THOR, this lncRNA is found in humans, mice and zebrafish. That this seemingly non-coding, “junk” gene has been evolutionarily conserved in three separate species is remarkable, and suggests there’s a biological importance associated with this lncRNA.

The team also found it curious that THOR was highly expressed in the testes and nowhere else in normal adult tissue. Yet, when they analyzed cancer tissues, particularly melanoma and lung cancer, THOR showed up in abundance.

Collectively, these lines of evidence suggest THOR is involved in cancer development in some way. Indeed, when the team modified cells to have THOR silenced, tumor growth was reduced. By contrast, when THOR is overexpressed, tumor growth was accelerated.

"If we perturb THOR function," said Dr. Arul Chinnaiyan, the study’s senior author, "we disturb the ability to stabilize RNA. This inhibits cell proliferation."

Furthermore, the effects of these alterations were not seen in normal cells, suggesting THOR may be limited to cancer cells. This would present a unique opportunity for therapy since blocking THOR would not seem to harm healthy cells.

The discovery not only helps to reinstate the importance of non-coding genomic sequences, but also has large implications for the clinical diagnosis and treatment of cancers.

Additional sources: MNT

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
MAR 19, 2020
Cancer
MAR 19, 2020
Declining death rates for melanoma
Fewer people are dying from melanoma in the United States, suggests new research from the Perlmutter Cancer Center at NY ...
APR 22, 2020
Cancer
APR 22, 2020
This model predicts those at high risk of pancreatic cancer
A new study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Can ...
APR 30, 2020
Cancer
APR 30, 2020
A New microRNA for the Cancer Fighting Toolkit
MiRNAs are small snippets of genetic information that regulate gene expression thought to be able to regulate up to 60% ...
MAY 06, 2020
Cancer
MAY 06, 2020
Olanzapine useful for cancer patients managing nausea unrelated to chemo
A study published last week in JAMA Oncology reports that a generic drug called Olanzapine could be useful for cancer pa ...
MAY 14, 2020
Clinical & Molecular DX
MAY 14, 2020
New Tech Has Its AI on Brain Tumors
  A collaboration across 29 research and healthcare agencies is putting together the world’s largest brain tu ...
MAY 03, 2020
Cancer
MAY 03, 2020
New genes targeted for anti-cancer therapies
Research published in the journal Genome Biology reports the discovery of two overlooked genes that have the potential t ...
Loading Comments...